These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 845257)

  • 1. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.
    Sissons JG; Liebowitch J; Amos N; Peters DK
    J Clin Invest; 1977 Apr; 59(4):704-15. PubMed ID: 845257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complement abnormalities of lipodystrophy.
    Sissons JG; West RJ; Fallows J; Williams DG; Boucher BJ; Amos N; Peters DK
    N Engl J Med; 1976 Feb; 294(9):461-5. PubMed ID: 1246331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
    Potter BJ; Elias E; Jones EA
    J Lab Clin Med; 1976 Sep; 88(3):427-39. PubMed ID: 956695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of properdin in normal subjects and patients with renal disease.
    Ziegler JB; Rosen FS; Alper CA; Grupe W; Lepow IH
    J Clin Invest; 1975 Sep; 56(3):761-7. PubMed ID: 1159085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
    Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 metabolism in ulcerative colitis and Crohn's disease.
    Hodgson HJ; Potter BJ; Jewell DP
    Clin Exp Immunol; 1977 Jun; 28(3):490-5. PubMed ID: 891024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 metabolism in acute glomerulonephritis: implications for sites of complement activation.
    Endre ZH; Pussell BA; Charlesworth JA; Coovadia HM; Seedat YK
    Kidney Int; 1984 Jun; 25(6):937-41. PubMed ID: 6236326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The many effects of complement C3- and C5-binding proteins in renal injury.
    Puri TS; Quigg RJ
    Semin Nephrol; 2007 May; 27(3):321-37. PubMed ID: 17533009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of complement fragment C5a in milk is variable among cows.
    Rainard P; Poutrel B
    J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hemolytic method for the measurement of nephritic factor.
    West CD
    J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
    Habib R; Lévy M; Gubler MC; Broyer M; Habib M
    Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement and leukocyte independent proteinuria and eicosanoid synthesis in rat membranous nephropathy.
    Rahman MA; Liu CN; Dunn MJ; Emancipator SN
    Lab Invest; 1988 Oct; 59(4):477-83. PubMed ID: 3050273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
    Geiger H; Good RA; Day NK
    Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.